# Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer

> **NCT04442581** · PHASE2 · TERMINATED · sponsor: **University of Washington** · enrollment: 2 (actual)

## Conditions studied

- Advanced Hepatocellular Carcinoma
- BCLC Stage B Hepatocellular Carcinoma
- BCLC Stage C Hepatocellular Carcinoma

## Interventions

- **DRUG:** Cabozantinib S-malate
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT04442581
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-04-20
- **Primary completion:** 2021-12-13
- **Final completion:** 2022-03-08
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Terminated due to slow accrual
- **Last updated:** 2023-04-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04442581

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04442581, "Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT04442581. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*